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The long-term evolution of the hepatitis C virus hypervariable region (HVR) and flanking regions of the E1
and E2 envelope proteins have been studied in a cohort of women infected from a common source of anti-D
immunoglobulin. Whereas virus sequences in the infectious source were relatively homogeneous, distinct HVR
variants were observed in each anti-D recipient, indicating that this region can evolve in multiple directions
from the same point. Where HVR variants with dissimilar sequences were present in a single individual, the
frequency of synonymous substitution in the flanking regions suggested that the lineages diverged more than
a decade previously. Even where a single major HVR variant was present in an infected individual, this lineage
was usually several years old. Multiple lineages can therefore coexist during long periods of chronic infection
without replacement. The characteristics of amino acid substitution in the HVR were not consistent with the
random accumulation of mutations and imply that amino acid replacement in the HVR was strongly con-
strained. Another variable region of E2 centered on codon 60 shows similar constraints, while HVR2 was
relatively unconstrained. Several of these features are difficult to explain if a neutralizing immune response
against the HVR is the only selective force operating on E2. The impact of PCR artifacts such as nucleotide
misincorporation and the shuffling of dissimilar templates is discussed.
More than 80% of individuals infected by hepatitis C virus
(HCV) become chronically infected (25), with outcomes vary-
ing from persistent asymptomatic infection to chronic hepati-
tis, cirrhosis, or hepatocellular carcinoma. This phenomenon
distinguishes HCV from other members of the Flaviviridae
such as yellow fever virus, dengue virus, or pestiviruses, which
do not normally establish persistent infections, but the reason
for this difference is unclear.
One possible mechanism for the establishment of persistent
infections by HCV relates to the most variable portion of the
HCV genome, the hypervariable region (HVR) at the NH2
terminus of the envelope protein E2 (9, 49). Nucleotide se-
quence analysis has revealed that many different HVR variants
can be present within an infected individual (15, 46), that the
relative proportion of each variant can change over time (8,
13), and that variation within the HVR tends to accelerate as
disease progresses, with few substitutions occurring during
acute infection (26, 30, 35, 51). These observations are consis-
tent with the idea that amino acid substitution of the HVR
allows variants to evade neutralizing immune responses, thus
leading to persistent infection.
This theory is supported by the observation that antibody to
the HVR is produced in the majority of viremic individuals (36,
54), suggesting that the HVR is a major immunogenic domain
of E2. Antibodies can be specific for different HVR variants
(22), and new specificities develop after the emergence of new
dominant HVR variants (1, 16, 39). The resolution of acute
infection has been associated with an early antibody response
to the HVR (1), specifically to the NH2 terminus (53), whereas
antibodies directed against the COOH terminus of the HVR
coexist with the virus in chronically infected individuals. Pro-
tection against infection with HCV has been demonstrated in
chimpanzees by using a hyperimmune serum against the HVR
(7), although no protection was conferred against some HVR
variants present in the challenge inoculum. There is also evi-
dence that in the absence of an antibody response to the HVR,
variation of the HVR is reduced (19, 52). In an experimentally
infected chimpanzee, variation of the HVR occurred only after
a delay of 6 years and after the appearance of anti-HVR
antibodies (48).
However, direct evidence for neutralization of HCV by anti-
HVR antibodies has been difficult to obtain in the absence of
an efficient in vitro culture system. Anti-HVR antibodies pro-
duced during acute infection have been shown to block viral
attachment to tissue culture cells (54), but in most cases anti-
HVR antibodies seem to coexist with the HVR variants that
they recognize and are frequently cross-reactive with epidemi-
ologically unrelated HVR sequences (22, 36, 53, 54). Alterna-
tive explanations for the generation of diversity in the HVR
are that different HVR variants have tropisms for particular
tissues (37) or that this region is simply less functionally con-
strained than other parts of the genome (40). Some of the
variation observed in individuals infected with multiple HVR
variants might be preexisting in the infectious source, and
different variants might become dominant as infection pro-
gresses and different foci of infection become active. In each of
these explanations, variation of the HVR would be an effect of
persistent infection rather than a cause. Finally, the impor-
tance of the cellular immune response in selecting HVR vari-
ants is uncertain. The cytotoxic T-lymphocyte response in the
hepatic parenchyma has been reported to recognize variable
regions of the envelope and nonstructural proteins (17). Pro-
liferation studies have shown that peripheral CD41 T lympho-
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cytes from chronically infected patients recognize the carboxyl
terminus of core and less frequently E1, E2, and NS3 (21).
Our understanding of the HVR in HCV infection has also
been hampered by a lack of information about the general
characteristics of HVR evolution. For example, although there
have been many studies of HVR evolution within a single
infected individual or following a transmission event, there
have been few studies in which virus evolution has been studied
in parallel in several individuals infected from the same source
(10). In addition, the extent of virus heterogeneity in the in-
fectious source is often unknown, although this could clearly
influence the complexity of the virus population during persis-
tent infection. Two extreme scenarios following infection from
a homogeneous source are (i) that different HVR variants
appear in each infected individual or (ii) that functional con-
straints and shared selection pressures lead to the emergence
of similar variants in different individuals.
This work aims to address these questions by studying virus
evolution in a cohort of Irish women, infected in 1977 from a
batch of anti-D immunoglobulin contaminated with HCV (32,
33). Sequence analysis of virus E1 and NS5B genes revealed
that different anti-D recipients were all infected with a subtype
1b virus which was more similar to virus sequences present in
an infective batch of immunoglobulin than to unrelated sub-
type 1b sequences (32, 44). Analysis of individual virus ge-
nomes by limiting dilution revealed relatively little variation of
NS5B sequences within the infective batch (44). This is con-
sistent with there being a single implicated donor who was
probably acutely infected (6). All the infectious batches were
manufactured with plasma collected over a period of 10 days
from the implicated donor 2 months after first becoming jaun-
diced and who at that time had an incomplete pattern of
serological reactivity consistent with acute infection. This co-
hort also has the advantage that it comprises women of a
similar age group with the same duration of infection and who
are not coinfected with other viruses or suffering from other
chronic diseases. We have therefore been able to study the
evolution of the HVR in parallel in different individuals and to
investigate the types of constraints placed on its variation.
MATERIALS AND METHODS
Samples. Plasma and serum samples were obtained in 1994 from Irish women
who had been exposed to an HCV-contaminated batch of anti-D immunoglob-
ulin in 1977 and were anti-HCV positive and HCV RNA positive for the 59
noncoding region by reverse transcription-PCR. Archived samples of batches 238
and 250 were reconstituted with 2 ml DEPC-treated water and made up to 7.5 ml
with RPMI medium. Virus was collected by ultracentrifugation at 100,000 g for
90 min.
Reverse transcription-PCR. Virus RNA was extracted either from 0.1 ml of
plasma or serum or, for four samples, from 0.5 to 2 ml by centrifugation at
100,000 3 g at 4°C for 90 min. Virus RNA was extracted by incubation with
proteinase K-polyadenylic acid-sodium dodecyl sulfate as reported previously
(12). Synthesis of cDNA was carried out with 5 ml of extracted RNA and 10 U
of avian myeloblastosis virus reverse transcriptase (Promega) in 20 ml of buffer
containing 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, 5 mM dithiothreitol, 50 mM
KCl, 0.05 mg of bovine serum albumin per ml, 15% dimethyl sulfoxide (DMSO),
600 mM each dGTP, dATP, dTTP, and dCTP, 1.5 mM primer, and 10 U of
RNasin (Promega). A fragment containing the COOH terminus of E1 and an
NH2-terminal region of E2 were amplified with primers 2174 (59-TTCATCCA
YGTRCASCCRAACCA-39, antisense, positions 1645 to 1667 numbered from
the AUG initiation codon) and 2173 (59-CAYCGNATGGCNTGGGAYATGA
TG-39, sense, positions 946 to 969) for the first round of PCR and primers 8914
(59-CGGGATCCGGGTGCTCACTGGGGAGTCCTGGCGGGC-39, sense, posi-
tions 1048 to 1074 incorporating a BamHI site) and 2070 (59-GGAATTCGTG
AARCARTACACYGGRCCRCANAC-39, antisense, positions 1504 to 1529 in-
corporating an EcoRI site) for the second round of PCR. Optimized conditions
for PCR amplification of the HVR involved 5 ml of cDNA and 30 cycles, each
consisting of 0.6 min at 94°C, 0.7 min at 50°C, and 1.5 min at 72°C, with a final
extension period of 6.5 min at 72°C. Reactions were carried out with 0.4 U of Taq
DNA polymerase (Promega) in 50 ml of buffer containing 50 mM KCl, 10 mM
Tris-HCl (pH 9.0), Triton X-100, 1.5 mM MgCl2, 30 mM each dGTP, dATP,
dTTP, and dCTP, and 0.25 mM each of the outer primers. For the second round
of PCR, 1 ml of PCR product was transferred to a fresh tube containing 100 ml
of reaction mix and subjected to 30 cycles of PCR as before.
Limiting-dilution PCR. cDNA was diluted until PCR products were derived
from single cDNA templates (41). Reaction conditions were as above except that
the reaction mix contained 1% DMSO and the second round of PCR was for 40
cycles with primers 2172 (59-CGGGATCCATGATGMTNAAYTGGTCNCC-
39, sense, positions 964 to 983) and 588 (59-GGYGSGTARTGCCAGCARTA
NGG-39, antisense, positions 1450 to 1472). For sequencing, the second round of
PCR was repeated with one of the primers biotinylated. Single-stranded DNA
was obtained by binding the PCR product to paramagnetic streptavidin-coated
beads (Dynabeads; Dynal) and releasing the unlabelled strand by treatment with
alkali. Dideoxynucleotide sequencing was performed with the Sequenase 2.0
enzyme (Amersham) in the presence of 10% DMSO.
Cloning and sequencing of PCR products. PCR products and plasmid pUC18
were cleaved with both BamHI and EcoRI (Promega) and purified from 0.8%
low-melting-point agarose (Gibco BRL). Ligations were performed with 50 ng of
vector, 300 ng of PCR insert, and 5 U of T4 DNA ligase (Promega), and the
mixtures were incubated at room temperature overnight. Ligation products were
transformed into competent TG1 cells and plated on Luria agar plates containing
200 mg of ampicillin per ml, 10 mg of 5-bromo-4-chloro-3-indolyl-b-D-galactopy-
ranoside (X-Gal), and 200 mM isopropyl-b-D-thiogalactopyranoside (IPTG).
Plasmid DNA was extracted from transformants producing white colonies by
alkali denaturation and sequenced by standard methods with the Sequenase 2.0
enzyme (Amersham) and primers DBS6 (59-CACTGGGGAGTCCTGGCGGG
C-39, positions 1054 to 1074), S6645 (59-TGCCARCTNCCRTTGGTRTT-39,
positions 1243 to 1262) and pUC reverse primer (59-CAGGAAACAGCTATG
AC-39). Nucleotide sequences were entered, aligned, and checked with Sim-
monic Performance1 software (version 1.0, P. Simmonds).
Phylogenetic analysis. Phylogenetic analysis was carried out with the Molec-
ular Evolutionary Phylogenetic Analysis (MEGA) version 1.02 package (18).
Evolutionary distances were calculated by the Kimura two-parameter method
(all sites) or the Jukes-Cantor correction (synonymous sites). Sliding-window
analysis of synonymous and nonsynonymous distances was carried out with the
program Windows (11).
Previously published sequences have the following references or GenBank
accession numbers: 1a sequences, references 15, 27, and 49, no. M62231,
M62381, A27609, D10749, L16891, L19371 to L19374, L19376-L19378, L198380,
L198381, M74804, M74805, M74808, M74811, M74812, S55848, S72725,
U14232, U14233, U14239, U51791 to U51795, and X84079; 1b sequences, ref-
erences 10 and 15, no. D50483-5, U45476, D30613, M58335, D001171, D10934,
S62220, L02836, M96362, and U01214; 2a sequence, no. D00944; 2b sequence,
no. D01221; 2c sequence, no. D50409; 3a sequences, references 3 and 5, no.
D17763, D14311, Z68743, Z68742, and D28917; 3b sequence, no. D26556; “10a”
sequence, no. D63821; 4a sequence, no. Y11604; 5a sequence, no. L29578, and
Y13184; 6a sequence, no. Y12083; “11a” sequence, no. D63822.
Nucleotide sequence accession numbers. The GenBank accession numbers of
the nucleotide sequences reported here are AF056733 to AF056925.
RESULTS
Homogeneity of the infectious source. Nucleotide sequence
analysis of the E1 and E2 envelope genes (positions 1096 to
1458) from two different infective batches of anti-D immuno-
globulin revealed limited variation between virus genomes
(Fig. 1, B250 and B238) with a mean evolutionary distance
between clones of 0.008. Within the hypervariable region,
amino acid sequences were identical in 21 clones and differed
by single sporadic amino acid substitutions in 3 different clones
(Fig. 2). These and seven other sporadic substitutions observed
in the region flanking the HVR are likely to represent artifacts
introduced by Taq DNA polymerase during PCR amplification
(see Discussion). Irrespective of this interpretation, variation
of the E1 and E2 genes, including the hypervariable region,
was extremely limited among the virus genomes present in
infective batches of anti-D immunoglobulin.
Variation among anti-D recipients. Much greater variation
was observed between E1 and E2 sequences from 17 different
anti-D recipients sampled 17 years after exposure (mean evo-
lutionary distance, 0.12). Phylogenetic analysis confirmed that
all sequences had a common branch that separated them from
40 epidemiologically unrelated subtype 1b sequences and that
this branch was observed in 94% of bootstrap resampling rep-
licates (Fig. 1). Since virus sequences in the infectious source
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were relatively homogeneous, differences between virus se-
quences in different individuals have mostly arisen during the
17 years of separate evolution from their common source.
Analysis of the frequency of substitution across the region
sequenced revealed that nonsynonymous substitutions that re-
sult in amino acid alterations were concentrated at the NH2
terminus of the E2 gene, corresponding to the HVR (data not
shown). In addition, there was considerable variability between
sequences from different anti-D recipients for codons 55 to 65
of E2 and to a lesser extent around codon 93, corresponding to
HVR2 (15). A similar pattern of variability was observed
among epidemiologically unrelated subtype 1b sequences
(data not shown).
Sporadic nonsynonymous substitutions, defined as substitu-
tions occurring in only 1 of the 153 clones sequenced, were
evenly distributed throughout the regions sequenced. Of the 80
sporadic substitutions, 3 resulted in termination codons; in
addition, there were 5 sporadic single-nucleotide deletions.
The frequency of these sporadic changes is consistent with
their origin as nucleotide misincorporation during PCR (see
Discussion). Other nonsynonymous substitutions were present
in two or more clones and presumably represent segregating
polymorphisms present in different virus genomes.
Synonymous substitutions were relatively evenly distributed
throughout the region sequenced except for the region of E1
immediately preceding the HVR. The frequency of synony-
mous substitutions between different anti-D recipients, exclud-
ing the HVR (mean, 0.154), was higher than previously docu-
mented for the same cohort in an adjoining region of E1
(0.053) or NS5B (0.037) (44). This trend is also observed upon
comparison of complete genome sequences of epidemiologi-
cally unrelated subtype 1b isolates (45).
FIG. 1. Phylogenetic analysis of E1 and E2 sequences from anti-D recipients and subtype 1b isolates. Evolutionary distances between representative sequences from
two anti-D immunoglobulin batches (B), 17 anti-D recipients (R), and 40 epidemiologically unrelated subtype 1b sequences in the E1/E2 region (nucleotide positions
1096 to 1458) were used to construct a neighbor-joining tree. The bootstrap support (100 replicates) for the group of sequences from anti-D recipients is indicated.
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Variation of the HVR. The diversity of HVR amino acid
sequences within individual anti-D recipients between the 3 to
19 different clones sequenced was generally quite limited (Fig.
2 and 3). For 12 recipients, a single major HVR variant was
present along with minor variants that differed at no more than
two positions. In three recipients (R78, R15 and R69), two
major variants were present, although these differed from each
other at only 2 or 3 positions, while in two recipients (R12 and
R803), there were two major variants that differed from each
other at 7 or 12 positions. Finally, in R344, four distinct vari-
ants were present, differing from each other at 5 to 10 posi-
tions.
Much greater divergence was observed between different
anti-D recipients. No two recipients had the same HVR se-
quence (Fig. 2), and the number of amino acid differences
between the variants infecting different recipients (mean, 9.8)
was almost as great as that between epidemiologically unre-
lated viruses within subtype 1a, 1b, or 3a (means, 12.0, 13.2,
and 13.3, respectively [Fig. 3]). This diversity was not present
among virus sequences isolated from the two infectious
batches (Fig. 2) and so must represent divergent evolution
during the 17 years of chronic infection. Surprisingly, the di-
vergence between HVR sequences in different anti-D recipi-
ents and that present in the infectious batch was only slightly
less (9.3 differences) than that between different recipients (9.8
differences), despite the period of divergence being only half as
long. This anomaly may reflect the existence of constraints
within the HVR that result in saturation of substitutions after
relatively short periods (see below). In addition, distances be-
tween the batch and recipients were distributed into two sep-
arate peaks, one having a mean of 13 differences and the other
having a mean of 7 differences, reflecting the lack of variation
at the NH2 terminus among several recipients (Fig. 2).
Constraints on HVR variation. Despite the diversity of
HVR amino acid sequences observed among the different an-
ti-D recipients, sequence change was not random but varied
depending on the position within the HVR. Six amino acids
(positions 2, 6, 20, 23, 24, and 26, numbered from the NH2
terminus of E2) were completely conserved among all HVR
sequences from the 17 different anti-D recipients (Fig. 2),
except for the occasional serine residue at position 20 and five
sporadic substitutions. At the majority of variable positions in
the HVR, amino acids were confined to two, three, or four
different residues with similar characteristics. At seven posi-
tions (positions 4, 7, 8, 10, 13, 17, and 21), almost all amino
acids were small uncharged residues (glycine, alanine, serine,
threonine, or valine). At another two positions (positions 3 and
11) amino acids were confined to large residues with a disso-
ciable proton (histidine, arginine, or tyrosine), while two other
positions (positions 16 and 19) were predominantly large hy-
drophobic residues (leucine, isoleucine, phenylalanine, or me-
thionine). At four positions, residues were confined to four or
fewer amino acids but with dissimilar characteristics (position
5, threonine or methionine; position 9, glutamine, threonine,
or methionine; position 12, threonine, asparagine, or alanine;
position 27, asparagine, lysine, arginine, or alanine). Finally, at
the remaining six positions (positions 1, 14, 15, 18, 22, and 25)
five or more amino acids occurred, again with no discernible
pattern. At three of these positions (positions 1, 18, and 22),
the amino acid residue present in the HVR sequence from the
infectious batch was present in 10% or fewer of the clones
sequenced from anti-D recipients.
Characteristics of substitution in the HVR. The observation
that amino acid substitutions at some positions in the HVR
were confined to particular amino acids might be related to the
ease with which these substitutions could be produced from the
nucleotide sequence of virus in the infectious batch. There is a
3- to 6-fold bias against transversion substitutions (A or G7C
or U) and toward transition substitutions (A7G or C7U) in
the HCV genome as a whole (4, 28, 30), rising to 16-fold at the
third position of codons (45), where confounding effects of
constraints on amino acid substitution are weakest. A change
of the tyrosine at position 3 of the HVR to histidine only
requires a single transition mutation, while a change to isoleu-
cine, threonine, alanine, or glycine would require two indepen-
dent transversion mutations. Hence, a change to histidine at
position 3 might be expected to occur more frequently than
changes requiring one or more transversions.
The validity of this explanation was investigated by compar-
ing the nucleotide sequence of the HVR from the infectious
batches with that present in clones from 17 different recipients.
Over the HVR as a whole, the ratio of transitions to transver-
sions was lower (median, 2.3) than for the flanking region
(median, 3.7) or for the HCV genome as a whole (median, 4.3)
(45). At nonsynonymous sites in the HVR, there were 179
transition substitutions compared to 122 transversions (Fig. 4),
similar to the ratio (1.4) observed at nonsynonymous sites
elsewhere in the genome (45), suggesting that change is not
random.
FIG. 3. Scatter plot of the number of amino acid differences between differ-
ent groups of HVR sequences. The number of amino acid substitutions in the
HVR (positions 383 to 408) was calculated for sequences of viruses of genotypes
1a (n 5 58), 1b (n 5 46) or 3a (n 5 16), among representative sequences from
different anti-D recipients (R-R), between these sequences and the consensus
sequence of the infectious source (B-R), and within individual anti-D recipients
(R).
FIG. 2. Phylogenetic analysis of E1/E2 sequences from anti-D recipients and infectious batches. Distinct HVR amino acid sequences (codons 1 to 27 of E2) found
in cloned virus sequences from two anti-D immunoglobulin batches and 17 recipients are compared with the most frequent sequence variant present in the batches
(identities shown by ., sequence ambiguities shown by ?, a stop codon shown by p, and single nucleotide deletions shown by #). Sequences derived from single cDNA
molecules by direct sequence analysis of PCR products obtained at limiting dilution are indicated by sm. The number of clones or direct sequences that share a given
HVR sequence is indicated. Amino acids underlined in the batch sequence are strongly conserved in the entire data set, while sporadic amino acid substitutions are
indicated by boldface type.
VOL. 72, 1998 LONG-TERM EVOLUTION OF HCV HYPERVARIABLE REGION 4897
Considering each codon separately (Fig. 4), at some sites the
pattern of substitution was consistent with the random accu-
mulation of mutations, since both synonymous and nonsynony-
mous substitutions occurred, with transitions outnumbering
transversions (codons 4, 5, 11, 12, 13, 14, 16, 17, and 20).
Hence, the observation that amino acid replacements at posi-
tions 4, 11, and 13 were limited to residues with similar bio-
chemical properties might instead reflect the biased pattern of
substitution during replication of the HCV genome. However,
one or more of the potential nonsynonymous transition muta-
tions did not occur at codons 12 (isoleucine absent), 14 (cys-
teine), 16 (proline), 17 (methionine), and 20 (leucine), suggest-
ing the presence of negative selection against certain amino
acid replacements at these sites. Another class of sites included
those where there were more transversion mutations than ex-
pected, in some cases multiple substitutions, even though one
or more of the three possible single transition mutations was
not observed (codons 1, 3, 7, 9, 10, 15, 18, 21, 25, and 27). This
pattern of substitution implies selection for or against partic-
ular amino acid replacements rather than random fixation or
selection for change per se. The most extreme example was
position 18, where although three different double mutations
occurred, no single transition substitutions were observed, and
where three different transversion substitutions occurred but
did not include either of the two potential synonymous trans-
versions. All three of the potential transition substitutions were
observed in at least one of the 150 clones sequenced at only
three codons. There were no substitutions at codon 6 in any of
the clones sequenced, while only synonymous substitutions
were observed at codons 2, 23, 24, and 26, implying strong
negative selection against amino acid replacement at these
positions.
Synonymous transition substitutions did not occur at 11 of
the 27 codons in the HVR, although other transitions or trans-
versions were observed at all codons except codon 6. This
deficiency may be partly due to a bias against U or A at the
third position of codons (45), since for 10 of these 11 codons
the third position was G or C. In contrast, of the 16 codons at
which a synonymous transition substitution was observed, 6
had U or A at the third position, similar to the relative fre-
quency over the HCV genome as a whole (45).
Another way of investigating the characteristics of substitu-
tion in the HVR is to compare distances between the batch
sequence and representative sequences from different anti-D
FIG. 4. Pattern of nucleotide substitution within the HVR. The number and type of substitutions occurring in different recipients at each codon of the HVR are
summarized schematically. The solid black squares represent the nucleotide sequence of the codon found in the infectious batch at each position. Synonymous transition
substitutions are represented by boxes on the horizontal axis to the left of the origin, while synonymous transversion substitutions are represented by boxes below the
origin on the vertical axis. Similarly, nonsynonymous substitutions are shown to the right of the origin if they are transitions and above the origin if they are transversions.
Where a codon contains multiple substitutions, this is indicated by adding the individual vectors, so that a nonsynonymous substitution produced by two transversion
substitutions is indicated by two boxes on the vertical axis above the origin (see the example below the figure). The number of times each combination of substitutions
was observed is indicated by the number in the corresponding box; identical substitutions occurring in different recipients were considered independent events, while
sporadic substitutions were ignored. The range of amino acid residues observed at each codon is indicated, with the residue found in the infectious batch in boldface
type. The ratio of the number of nonsynonymous to synonymous substitutions between the batch sequence and representative sequences from each recipient is indicated
for each codon.
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recipients at synonymous (dS) and nonsynonymous (dN) sites.
Over the HVR as a whole, the ratio of dN to dS was 2.0, or 2.5
if the six completely conserved sites were excluded. This com-
pares with an average of 1.13 for the next 76 codons of E2 and
less than 0.25 for comparisons between complete genomes
(45). Comparing codons individually, the number of nonsyn-
onymous substitutions was more than twice the number of
synonymous substitutions at 18 positions and lower ratios were
observed only at the 6 invariant codons and at codons 5, 7, and
12, which were the next most strongly conserved (Fig. 4).
This data suggests that for the majority of positions in the
HVR the restricted pattern of amino acid substitution ob-
served among the anti-D recipient cohort is not simply a con-
sequence of the biased pattern of nucleotide substitution in the
HCV genome. Instead, there is evidence for positive selection
for particular amino acid replacements at the majority of po-
sitions and for negative selection against amino acid replace-
ment at other positions.
Variation of the regions flanking the HVR. While the
COOH-terminal 18 residues of the E1 polypeptide were highly
conserved with only one site variable, 33 of the 76 positions in
E2 following the HVR were polymorphic. All but three of
these sites were also polymorphic in a set of 40 epidemiolog-
ically unrelated subtype 1b sequences, and in the majority of
cases the same amino replacements occurred. Four potential
N-linked glycosylation sites at positions 34 to 35, 40 to 42, 47 to
49, and 65 to 67 were conserved except for eight sporadic
substitutions and three segregating polymorphisms, while cys-
teine residues at positions 46, 69, 76, and 103 were also con-
served except for four sporadic substitutions. A cluster of these
conserved residues between positions 34 to 49 and immediately
following the HVR coincides with the region of lowest vari-
ability in E2. All but two of the anti-D recipient had distinct
sequences in the region between positions 51 and 63, which
also differed from that present in the infective batch, while for
HVR-2 several of the anti-D recipients had identical se-
quences, although these differed from the infectious batch
sequence by one to four substitutions.
Origin of HVR variants within an individual. Phylogenetic
analysis of sequences from anti-D recipients, excluding the
HVR, produced distinct groupings of sequences for most re-
cipients, seven of which were supported by bootstrap resam-
pling of replicates of synonymous sites (Fig. 5) or of all sites
(data not shown). Two separate groups of sequences were
observed for R69, while four different groups were observed
for R344, some of which were supported by bootstrap resam-
pling. These groups correspond to the groups of distinct HVR
variants detected within these recipients. Less extreme sub-
groupings of flanking region sequences were observed for R12,
R15, R78, R344, and R803, and these groups of sequences
corresponded to the groups of HVR variants present in these
individuals (Fig. 2). Exceptions to this segregation were a clone
from R12 that grouped separately from three clones from
which it differed in the HVR by only two sporadic substitu-
tions, two clones from R78 that grouped with clones bearing
HVR sequences differing at two sites, and one clone from R69
that grouped with clones differing in their HVR sequence at
four positions rather than with clones differing at only two
positions. These exceptions may have arisen through template
shuffling during PCR (see Discussion).
Substitutions at synonymous sites flanking the HVR might
be expected to have little effect on virus viability and to accu-
mulate linearly with time. In support of this possibility, evolu-
tionary distances at synonymous sites between flanking region
sequences from different recipients averaged 0.16 compared to
0.105 between recipients and the infectious batch, consistent
with the greater period of separation between virus sequences
in different recipients. Using the rate of accumulation of sub-
stitutions between different recipients to estimate the time of
divergence between distinct HVR variants within a single re-
cipient gives times of 8.5 to 9.5 years for the variants in R12, 15
years for the variants in R803, and 11 to 15 years for the
variants in R344. Similar times of divergence (10 to 16 years)
are implied for the variant groups in R15, R69, and R78 that
differed at two or three positions. Estimated times of diver-
gence were lower in individuals in whom a single HVR variant
was detected, with times of 2 years or less in four recipients,
less than 5 years in a further five recipients, and less than 9
years in a further two recipients (mean, 3.3). These times of
divergence were shorter than those estimated within groups of
sequences with similar HVR sequences for recipients infected
with two or more HVR variant groups (1.7 to 10.2 years; mean,
5.9).
DISCUSSION
Artifacts and the interpretation of HVR variation. We have
found evidence for two types of artifact among our sequence
data, both of which probably arose during PCR amplification.
First, 90 sporadic nonsynonymous substitutions were observed
in the sequence data set, 3 of which produced termination
codons while there were 5 deletions of a single base pair.
Although these might represent minor sequence variants in the
virus population, their frequency is consistent with their origin
during PCR because of nucleotide misincorporation by Taq
DNA polymerase, equivalent to an error rate of 3.5 3 1025 per
nucleotide per cycle of amplification, within the documented
range (2 3 1025 to 20 3 1025) (42). We tested this interpre-
tation for three different recipients by direct sequencing of 7 to
10 PCR products obtained at limiting dilution of virus cDNA.
Since these PCR products are expected to be derived from a
single cDNA molecule, errors introduced by Taq during PCR
would be visible as a heterogeneity on the sequence gel only if
they occurred in the first cycle of PCR but would otherwise be
diluted out (41). Only 2 sporadic nonsynonymous substitutions
were observed among 27 sequences obtained at limiting dilu-
tion, while more than 10 would be expected from the same
number and length of cloned sequences. Similar frequencies of
sporadic substitution were observed in several other studies of
the diversity of the HVR within infected individuals (42) sug-
gesting that diversity in this part of the genome may be lower
than was previously suggested.
Another way in which artifacts can be generated during PCR
is through shuffling of templates due to the annealing of in-
completely extended products to heterologous templates (23).
Evidence for this type of artifact comes from the rare cases in
which polymorphisms in the HVR did not segregate with those
in the flanking region. These exceptions are unlikely to repre-
sent the products of convergent evolution since polymorphisms
in the flanking region switched as a large block from being
typical of one HVR variant group to being typical of another.
Sequences of this type could also result from recombination in
vivo, but apart from one report (15), there is no evidence for
recombination between HCV genomes (34, 43). In addition,
when 7 to 10 virus sequences were obtained at limiting dilution
for three anti-D recipients (R68, R69, and R803), conditions
which should allow the detection of in vivo recombinants but
prevent the shuffling of dissimilar templates during PCR, the
HVR variant groups segregated with the same flanking region
polymorphisms as for the sequences derived from cloned PCR
products (data not shown).
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FIG. 5. Phylogenetic analysis of the HVR flanking region at synonymous sites. Evolutionary distances between sequences at synonymous sites between positions
1096 to 1150 and 1231 to 1458 were calculated with the Jukes-Cantor correction for representative sequences from different anti-D recipients (R), two infectious batches
(238 and 250), and five unrelated subtype 1b sequences and used to construct a neighbor-joining tree. Sequences from the same recipient are grouped by vertical bars,
except where these group separately on the tree, in which case a suffix indicates the HVR group to which the sequences belong. Bootstrap values of 70% or more (500
replicates) are indicated.
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The HVR has multiple evolutionary pathways. HVR se-
quences from each anti-D recipient were distinct and were
almost as different from each other as were epidemiologically
unrelated subtype 1b sequences (Fig. 3). This diversification
occurred although all individuals were infected from a com-
mon source of limited diversity (Fig. 2) that would have pre-
sented the same antigenic stimulus upon first infection. This
observation implies that the HVR of HCV is not constrained
to follow a particular sequence of substitution in response to
selective pressures imposed during infection, as typified by the
sequential evolution of the influenza A virus hemagglutinin
from year to year (2). Instead, it appears that although amino
acid replacements are highly constrained (see below), the
HVR can evolve in multiple directions from a given starting
point.
Sequence change of the HVR is not random. Despite the
widespread acceptance of the idea that changes within the
HVR are driven by antibody-mediated selection (8, 19, 47, 48,
50, 53), direct evidence in support of this possibility has been
difficult to obtain in the absence of an in vitro culture system
(54). Alternative explanations include the possibility that vari-
ation of the HVR is involved in cell tropism, as suggested for
the V3 loop of human immunodeficiency virus, or that this
region is unconstrained so that nonsynonymous substitutions
occur in this region at the higher rate normally observed for
synonymous substitutions (45).
Because of the strong bias against transversion substitutions
in the HCV genome, this last explanation implies that the
amino acid replacements should be those that can be produced
by transition substitutions. Our study provides an opportunity
to test this possibility because the HVR of virus in the infec-
tious source was homogeneous, so that HVR substitutions
observed in different anti-D recipients can be assumed to have
arisen by independent events. At the majority of codons in the
HVR, the pattern of substitution was inconsistent with the
random accumulation of substitutions in the HVR (Fig. 4);
instead, amino acid replacements were generally limited to
particular sets of amino acids with shared biochemical prop-
erties or were completely conserved (Fig. 6). In addition, evo-
lutionary distances between the batch sequence and sequences
present in different recipients at nonsynonymous sites were
twice those at synonymous sites, compared with ratios of less
than 0.25 elsewhere in the virus genome. The bias toward
nonsynonymous substitution in the HVR is even stronger than
suggested by this ratio, since several positions were completely
conserved and only certain types of amino acid replacement
occurred at others. These observations are inconsistent with
the possibility that the HVR evolves by random drift and
suggest instead that substitutions are influenced by both neg-
ative and positive selection.
This interpretation is supported by the observation that very
similar constraints on amino acid replacement were observed
among a collection of 46 epidemiologically unrelated se-
quences of subtype 1b (Fig. 6). Five of the six positions that
were strongly conserved among the anti-D recipients were also
conserved among collections of sequences from other virus
genotypes. At codons where replacements among the anti-D
recipients were limited to particular groups of amino acids with
shared characteristics, the same restrictions were observed
among sequences from other genotypes. For example, replace-
ments at positions 4, 5, 13, 17, and 21 were usually small
hydrophobic residues while replacements at codons 16, 19, and
20 were typically either leucine, phenylalanine, or isoleucine.
Similar observations have been made for sequences from HCV
isolates of undefined genotypes (37, 38). At several positions
where seven or more amino acid replacements were observed
(codons 4, 8, 9, 12, 14, 21, 22, and 25), the most frequent amino
acid replacement differed between genotypes although the
general characteristics of the amino acids were maintained.
These constraints are reflected in the overall amino compo-
sition of the HVR, which differs consistently from that of the
entire E2 gene or the complete HCV polyprotein. For the
collections of HVR sequences from genotypes 1a, 1b, and 3a,
cysteine and tryptophan were almost completely absent, while
there was marked underrepresentation of aspartic and glu-
tamic acids and, to a lesser extent, of leucine, isoleucine, and
proline. Phenylalanine, glycine, and threonine were overrepre-
sented, although this is difficult to interpret since these amino
acids were strongly conserved at one or more codons. While
basic residues occurred at about the same frequency as for E2
as a whole, it was noticeable that they were common only at the
most variable sites, where seven or more different amino acid
replacements were observed in the collections of sequences.
There was also a bias in the pattern of substitution observed
within the HVR among the anti-D recipient cohort. While all
recipients had several substitutions in the region from codons
10 to 22, several recipients had no or very few substitutions
from codons 2 to 9. This observation is consistent with a study
of another cohort of anti-D recipients in which reactivity to the
COOH terminus of the HVR was more frequent among chron-
ically infected recipients than was reactivity to the NH2 termi-
nus (53). Several other studies have also mapped linear anti-
body epitopes to the COOH terminus of the HVR in both
acutely (14, 36, 37) and chronically (50) infected patients, as
well as in experimentally infected chimpanzees (47). Despite
these observations, comparison of HVR sequences from vi-
ruses of different genotypes provided no evidence for greater
heterogeneity at COOH-terminal positions within the HVR
(Fig. 6).
Hypervariable codons outside the HVR. Substitutions be-
tween sequences from anti-D recipients or between epidemi-
ologically unrelated subtype 1b isolates did not occur evenly in
the regions flanking the HVR but were concentrated in two
regions centered on codons 60 and 93 (HVR-2). Substitutions
occurring in the region around codon 60 tended to occur be-
tween a restricted set of amino acids with common character-
istics, such as lysine-arginine (codon 63), alanine-serine
(codons 57 and 66), or glutamine-asparagine-histidine-tyrosine
(codons 51 and 62). Some of these groups of amino acids were
also observed at one or more positions in the HVR, and the
extent of variability at individual codons was also similar. In
contrast, no common characteristic could be discerned for the
substitutions occurring at any of codons 93 to 97, and replace-
ments included nonpolar, polar, and charged residues, suggest-
ing that this region is subject to different constraints and/or
selection pressures. Elsewhere in E2, substitutions were either
rare or confined to closely related pairs of amino acids such as
aspartate-glutamate and isoleucine-valine.
Phylogenetic implications of constraints on sequence
change in E2. Because the HVR of E2 is the most variable
region of the HCV genome, it has been used by many groups
to investigate the phylogenetic relationship between virus se-
quences in different infected individuals. However, the obser-
vation that sequence change of the HVR is not random means
that similarity between sequences may not always reflect their
true phylogenetic relationship since substitutions may be con-
vergent and will quickly become saturated. For example, al-
though all anti-D recipients were infected from the same
source, most of the sequences obtained 17 years after infection
were as divergent from each other (mean, 9.8 differences) as
from the infectious batch (mean, 9.3) (Fig. 3). This degree of
divergence is smaller than between epidemiologically unre-
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lated subtype 1b sequences (mean, 13.9), but only because few
substitutions occurred in the NH2-terminal region of the HVR
in some recipients. HVR sequences from different recipients
were as different from the consensus HVR sequence of sub-
type 1b isolates (10.3 differences) as was the sequence of the
infectious batch (11 differences). Phylogenetic analysis of HVR
amino acid sequences from anti-D recipients failed to provide
bootstrap support for a common grouping, even if flanking
regions were included (data not shown), although their group-
ing was supported by 80% of bootstrap replicates if only syn-
onymous sites were considered (Fig. 5). Despite the limited
time of divergence between HVR sequences in different anti-D
recipients, at 21 of 27 codons the amino acids observed among
the cohort accounted for more than 75% of the range observed
among epidemiologically unrelated subtype 1b sequences.
Only at position 9 did replacements in the cohort account for
less than half of the subtype 1b sequences (Fig. 6).
These observations imply that amino acid substitutions in
the HVR become saturated within relatively short periods of
divergence and suggest that this region may not always be
reliable for the investigation of transmission events. For exam-
ple, in one study of vertical transmission, the HVR from an
infected infant differed at five to seven positions from the virus
sequences present in the mother (51) but epidemiologically
unrelated subtype 1a and 1b sequences sometimes differ to the
same extent (Fig. 3). Similarly, two patients of an HCV-in-
fected surgeon were infected with variants differing at only one
position in the HVR from one of the five variants present in
the surgeon but in other patients there were three, four, or five
differences (5). This situation was not clarified by analysis of a
188-nucleotide fragment including the HVR, since in some
cases distances between sequences from the surgeon and his
infected patients were equivalent to those between some epi-
demiologically unrelated controls. In both of these examples,
virus sequences were obtained relatively close to the time of
transmission, and greater problems of interpretation can be
expected in cases where samples from the implicated donor
and recipient are separated by several years or where the
implicated source is infected with a complex mixture of vari-
ants.
Limited diversity within persistently infected individuals. A
surprising finding of this study was that sequence diversity of
the HVR was quite limited within chronically infected anti-D
recipients, with the majority of recipients being infected with a
single major variant. This observation does not simply reflect
the recognition of sporadic substitutions as Taq errors in this
study, and it contrasts with several previous reports in which
multiple divergent HVR variants were found to cocirculate in
chronically infected individuals (15, 20, 24, 29). One explana-
tion for this difference may be the relatively homogeneous
nature of the infectious source in comparison to other studies,
where individuals were often infected with large quantities of
virus from potentially heterogeneous sources. For example, an
individual infected by blood transfusion from a chronically
infected individual might be expected to become infected with
the full range of variants present at that time. Another expla-
nation for the limited diversity observed in our study is that the
anti-D recipients formed a relatively homogeneous cohort,
since they were all women of a similar age and ethnic back-
ground, and did not have the complicating effects of factors
such as coinfection with other parenterally transmitted viruses,
nonviral chronic diseases such as hemophilia or renal failure,
or symptomatic chronic liver disease. For example, increased
variation of the HVR has been observed in individuals coin-
fected with HIV (38).
Long-term coexistence of multiple HCV lineages. Of the 17
anti-D recipients, 3 were infected with multiple HVR variants
differing from each other at five or more positions, while vari-
ant groups differed by two or three positions in three further
recipients. Phylogenetic analysis of sequences flanking the
HVR produced groupings of sequences that matched those
defined by HVR sequences, suggesting that distinct HVR vari-
ants represent different lineages and that convergent evolution
is uncommon. Using the extent of divergence at synonymous
sites in the region flanking the HVR to estimate the time of
divergence of HVR variant lineages gives times ranging be-
tween 8 and 16 years (mean, 12.1). In contrast, virus sequences
in individuals infected with a single HVR variant group were
more closely related to each other, with a mean estimated time
of divergence of 3.3 years. These observations imply that HVR
variant sequences can be stable for several years and that
variants with divergent HVR sequences can coexist in an in-
fected individual while following separate evolutionary path-
ways.
Nature of selection on HVR variants. Several of our obser-
vations on the long-term evolution of the HVR in individuals
infected from a common source cannot be explained if immune
system-mediated neutralization is the only selective force on
variants with different HVR sequences. First, variation was
unequally distributed within the HVR, with some positions
being invariant and others being highly variable and usually
limited to particular amino acid replacements. This pattern of
variation does not simply result from the bias toward transition
substitutions in the HCV genome. The pattern is also not due
to the homogeneity of the infectious source or the limited
period of divergence between sequences, since similar restric-
tions on amino acid replacement are observed among epide-
miologically unrelated sequences of subtype 1b or of more
distantly related virus genotypes (Fig. 6). Instead these obser-
vations imply that there is strong negative selection against
some amino acid substitutions in the HVR while at the major-
ity of codons there is selection for conservative amino acid
replacements rather than selection for change per se. In sup-
port of this idea, the amino acid present in the infectious batch
of anti-D at codons 1, 18, and 22 was rare (,5%) among HVR
sequences of other subtype 1b isolates and these codons were
the most frequently substituted (.90% of clones) among the
anti-D recipient cohort.
A second finding that is difficult to explain by immune se-
lection is that divergent HVR variants infecting a single anti-D
recipient belonged to different lineages that had coexisted for
8 to 15 years. These multiple lineages would be unlikely to
survive in the face of a neutralizing immune response since an
effective response against one variant should lead to a dramatic
shift in the composition of the virus population. With repeated
cycles of neutralization and immune system escape, it might be
expected that one of the variants would be eliminated. Multi-
ple lineages could coexist if convergent evolution led to similar
HVR sequences appearing in different lineages, but we have
found no evidence for this possibility.
Finally, considerable diversity in the region flanking the
HVR was observed even between HVR variants with similar
sequences, with 7 of 11 lineages being estimated to have arisen
2 years or more ago and 3 of these to have arisen more than 4
years ago. These estimates imply that selection for new HVR
variants is an infrequent event rather than a continuous pro-
cess and are difficult to reconcile with the observation that
antibody to the HVR is produced in the majority of infected
individuals (36, 54), that antibody specific for an HVR variant
can be present before the variant appears (16, 36, 52), that it
can coexist with the variant (37), or that increased variation of
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the HVR is observed in patients coinfected with human im-
munodeficiency virus (38).
Together, these observations are consistent with there being
strong selection for the maintenance of certain (unknown)
properties of the HVR at the same time as there is intermittent
positive selection for amino acid replacement. Further work is
required to clarify the properties of this region that produce
constraints on its evolution, as well as on the nature of the
selective forces that are responsible for amino acid replace-
ment. For example, sequence change in the HVR could result
from selection against peptides capable of binding to host
major histocompatibility complex alleles. This type of selec-
tion, which has been documented for human immunodefi-
ciency virus (31), might explain the long-term coexistence of
HVR variant lineages within an infected individual, since HVR
variants containing peptide epitopes incapable of binding to
class I or class II alleles would not be subject to further im-
mune selection. This hypothesis could be tested by investigat-
ing the association between particular HVR substitutions and
HLA type in this study group.
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